FDAnews
www.fdanews.com/articles/174548-fda-awards-orphan-drug-designation-to-tapimmune-cancer-vaccine

FDA Awards Orphan Drug Designation to TapImmune Cancer Vaccine

December 16, 2015

TapImmune has scored FDA orphan drug designation for its cancer vaccine TPIV 200 for ovarian cancer.

The multi-epitope peptide vaccine targets folate receptor alpha, a protein overexpressed in multiple cancers, including more than 90 percent of ovarian cancer cells.